Psilera Inc., a biotechnology company developing therapies for hard-to-treat neurological disorders, and atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, have signed a licensing agreement under which atai has acquired Psilera’s DMT (N,N-dimethyltryptamine) patent portfolio, including all granted and pending patents related to DMT and other related psychedelics. “We’re pleased to collaborate with atai...